CN113121666A - 抗菌肽Scybaumancin105-127及其应用 - Google Patents
抗菌肽Scybaumancin105-127及其应用 Download PDFInfo
- Publication number
- CN113121666A CN113121666A CN202110261150.8A CN202110261150A CN113121666A CN 113121666 A CN113121666 A CN 113121666A CN 202110261150 A CN202110261150 A CN 202110261150A CN 113121666 A CN113121666 A CN 113121666A
- Authority
- CN
- China
- Prior art keywords
- scybaumancin
- antibacterial peptide
- antibacterial
- drug
- antimicrobial agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 43
- 241000588626 Acinetobacter baumannii Species 0.000 claims abstract description 19
- 241000894006 Bacteria Species 0.000 claims abstract description 13
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 9
- 241000186779 Listeria monocytogenes Species 0.000 claims abstract description 9
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 9
- 241000221204 Cryptococcus neoformans Species 0.000 claims abstract description 8
- 241000194031 Enterococcus faecium Species 0.000 claims abstract description 8
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- 201000007336 Cryptococcosis Diseases 0.000 claims abstract description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 7
- 241000607762 Shigella flexneri Species 0.000 claims abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 235000013373 food additive Nutrition 0.000 claims description 10
- 239000002778 food additive Substances 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 8
- 239000004599 antimicrobial Substances 0.000 claims description 7
- 241000192125 Firmicutes Species 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 17
- 229940121657 clinical drug Drugs 0.000 abstract description 11
- 241001672730 Scylla paramamosain Species 0.000 abstract description 7
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 3
- -1 Amino Chemical group 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003677 hemocyte Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009435 amidation Effects 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- AAXVGJXZKHQQHD-LSJOCFKGSA-N Ala-His-Met Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)O)N AAXVGJXZKHQQHD-LSJOCFKGSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- MBPKYKSYUAPLMY-DCAQKATOSA-N Cys-Arg-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O MBPKYKSYUAPLMY-DCAQKATOSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000238102 Scylla Species 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3535—Organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了抗菌肽Scybaumancin105‑127及其应用，该抗菌肽首次发现于拟穴青蟹(Scylla paramamosain)，分子式为C106H188N36O28S3，其氨基酸序列如SEQ ID NO.1所示。本发明的抗菌肽Scybaumancin105‑127对鲍曼不动杆菌、福氏志贺氏菌、大肠埃希菌、铜绿假单胞菌、新型隐球菌、单核细胞李斯特氏菌、屎肠球菌及痤疮丙酸杆菌具有良好的抗菌活性，对正常细胞无细胞毒性。该抗菌肽Scybaumancin105‑127抗菌活性高、安全无毒，对临床耐药性细菌也具有较强的抗菌活性，具有广阔的应用前景。
Description
技术领域
本发明属于海洋分子生物学技术领域，具体涉及多肽及其应用。
背景技术
自1928年，弗莱明发现青霉素以来，抗生素的普及和应用挽救了无数的生命，推动了现代医疗的发展。然而，在持续性使用抗生素的过程中，抗生素的不当或过度使用，使得细菌耐药性基因被不断富集和传播扩散，导致临床中出现了大量的耐药性细菌，给临床治疗带来巨大挑战，甚至出现了无药可用的境地。细菌耐药性问题已在全球范围蔓延，2017年，世界卫生组织发表了首份抗生素耐药“重点病原体”清单，公布了12种对人类健康构成极大威胁的细菌种族目录，极为重要的1类重点清单包括碳青霉烯类药物耐药鲍曼不动杆菌、碳青霉烯类药物耐药铜绿假单胞菌、碳青霉烯类药物耐药/产超广谱β-内酰胺酶(ESBL)肠杆菌科细菌；万古霉素耐药屎肠球菌、甲氧西林耐药/万古霉素中介和耐药金黄色葡萄球菌位于十分重要的2类重点清单中。每年至少有70万人死于耐药性细菌感染，世界卫生组织预测，如不采取有效措施，这一数目在2050年将达到1000万。细菌对抗生素耐药的严峻形势，使得开发新型抗生素来替代传统抗生素变得尤为迫切。
抗菌肽(Antimicrobial Peptide，AMP)又称为宿主防御肽，广泛存在于动物、植物、微生物等生物体中，通常为具有两亲性的阳离子多肽，作为天然免疫的效应分子，具有广谱的抗菌、抗病毒、抗寄生虫、抗肿瘤活性；此外，还具有促进伤口愈合、抗炎及免疫调控等功能，相比于抗生素，抗菌肽抗菌机制多样、具有多个作用靶点、抗菌谱广、不易产生耐药性，被认为是良好的抗生素天然替代品。
自1981年，首个动物抗菌肽——天蚕素被分离得到后，大量抗菌肽被分离和鉴定，随着抗菌肽研究的开展，其功能被不断阐明，除了直接杀菌作用还具有免疫调控作用。同时，抗菌肽结构简单、化学合成方便快捷、杀菌迅速、不易产生耐药性等特点为其应用提供了更多的可能性。已有多种天然多肽、人工合成或设计改造的多肽进入临床试验，用于创面细菌性感染、痤疮、软组织感染、过敏性皮肤炎等疾病的治疗。鉴于其潜在的临床应用价值，开展抗菌肽的研究，获得活性高、安全性高的抗菌肽，以缓解临床耐药性问题，具有重要的意义。
发明内容
本发明的目的在于克服现有技术的不足之处，提供了抗菌肽Scybaumancin105-127及其应用。
本发明解决其技术问题所采用的技术方案之一是：
一种抗菌肽Scybaumancin105-127，分子式为C106H188N36O28S3，其氨基酸序列如SEQ IDNO.1所示，具体为:
Val-Val-Thr-Cys-Arg-Leu-Ala-His-Met-Ala-Leu-Lys-Ser-Ala-Lys-Ser-Ser-Arg-Ser-Leu-Leu-Cy s-His-NH2
本发明的拟穴青蟹抗菌肽Scybaumancin105-127由23个氨基酸组成，分子量为2511.06道尔顿，含2个赖氨酸、2个精氨酸和2个半胱氨酸残基，C端酰胺化修饰(-NH2)(即第23位的组氨酸His经-NH2修饰)。HeliQuest预测该抗菌肽电荷数为+4，疏水性为0.471。
所述抗菌肽Scybaumancin105-127可以以固体(如粉末等)、液体(如水溶液等)等多种形式应用。
本发明解决其技术问题所采用的技术方案之二是：
一种抗菌肽Scybaumancin105-127在制备抗菌剂中的应用。
本发明提供的一种新型抗菌肽Scybaumancin105-127，作为一种新型的抗菌活性物质，可以用于制备抗菌剂，作为抗菌剂中的有效成分，用于抑制或杀灭革兰氏阳性菌、革兰氏阴性菌或真菌。
本发明解决其技术问题所采用的技术方案之三是：
一种抗菌剂，所述抗菌剂包括氨基酸序列如SEQ ID NO.1所示的新型抗菌肽Scybaumancin105-127。
所述抗菌剂可抑制或杀灭革兰氏阳性菌、革兰氏阴性菌或真菌中的至少一种。
本发明所述的革兰氏阴性菌包括鲍曼不动杆菌、耐药鲍曼不动杆菌、福氏志贺氏菌、大肠埃希菌、耐药大肠埃希菌或铜绿假单胞菌中的至少一种；所述的真菌包括新型隐球菌；所述的革兰氏阳性菌包括单核细胞增生李斯特氏菌、屎肠球菌、耐药屎肠球菌或痤疮丙酸杆菌中的至少一种。
本发明所述的抗菌剂可以是药物形式的抗菌剂，即作为抗菌药物，也可以是非药物形式的抗菌剂，例如作为消毒产品，或作为纺织品、塑料等产品的添加剂等。
本发明解决其技术问题所采用的技术方案之四是：
一种抗菌肽Scybaumancin105-127在制备食品添加剂中的应用。
本发明提供的一种新型抗菌肽Scybaumancin105-127，安全性好，可以作为一种新型的食品添加剂，抑制和/或杀灭食源性污染微生物，尤其对食源性污染的单核细胞增生李斯特氏菌具有较强的杀菌活性。
本发明解决其技术问题所采用的技术方案之五是：
一种食品添加剂，所述食品添加剂包括氨基酸序列如SEQ ID NO.1所示的抗菌肽Scybaumancin105-127。所述食品添加剂尤其适合用于抑制和/或杀灭食源性污染的单核细胞增生李斯特氏菌。
本发明所涉及的设备、试剂、工艺、参数等，除有特别说明外，均为常规设备、试剂、工艺、参数等，不再作实施例。
本发明所列举的所有范围包括该范围内的所有点值。
本发明所述“大约”、“约”或“左右”等指的是所述范围或数值的±20％范围内。
本发明中，除有特别说明外，％均为质量百分比。
本技术方案与背景技术相比，它具有如下优点：
1.本发明的拟穴青蟹抗菌肽Scybaumancin105-127水溶性好、抗菌谱广、抗菌活性高且安全无毒，是一条具有广阔应用前景的阳离子短肽。
2.本发明的拟穴青蟹抗菌肽Scybaumancin105-127对单核细胞增生李斯特氏菌、屎肠球菌、福氏志贺氏菌、鲍曼不动杆菌、大肠埃希菌、铜绿假单胞菌、新型隐球菌及痤疮丙酸杆菌具有较强的抗菌活性，对HEK-293T、拟穴青蟹血细胞、EPC细胞无细胞毒性。
附图说明
图1为抗菌肽Scybaumancin105-127对鲍曼不动杆菌和新型隐球菌的杀菌动力学曲线，横坐标为时间(min)，纵坐标为CFU(菌落形成单位)/mL。
图2为抗菌肽Scybaumancin105-127处理鲍曼不动杆菌非临床耐药菌株CGMCC1.6769和临床耐药菌株QZ18050引起的形态结构变化。其中，A为鲍曼不动杆菌非临床耐药菌株，B为鲍曼不动杆菌非临床耐药菌株+6μM Scybaumancin105-127，C为鲍曼不动杆菌临床耐药菌株，D为鲍曼不动杆菌临床耐药菌株+12μM Scybaumancin105-127。
图3为MTS法检测拟穴青蟹抗菌肽Scybaumancin105-127对HEK-293T细胞、拟穴青蟹血细胞(Hemocytes)和EPC细胞的细胞毒性实验；横坐标为Scybaumancin105-127蛋白浓度(μM)，纵坐标为细胞存活率(cell viability)(％)。
具体实施方式
下面结合附图和实施例对本发明作进一步说明。
实施例1：拟穴青蟹抗菌肽Scybaumancin105-127
本实施例的一种拟穴青蟹抗菌肽Scybaumancin105-127的氨基酸序列如SEQ IDNO.1所示，具体为：
V-V-T-C-R-L-A-H-M-A-L-K-S-A-K-S-S-R-S-L-L-C-H-NH2，C端酰胺化修饰(-NH2)。
本实施例委托南京金斯瑞有限公司以固相合成方法合成获得纯度达95％以上的拟穴青蟹抗菌肽Scybaumancin105-127，并提供多肽分子量、HPLC等检测信息，用Helixquest预测其电荷和疏水性，其他理化参数均用ProtParam预测，拟穴青蟹抗菌肽Scybaumancin105-127理化参数如表1所示。
表1拟穴青蟹抗菌肽Scybaumancin105-127理化参数
实施例2：Scybaumancin105-127最小杀菌浓度(MBC：Minimum BactericidalConcentration)的测定
1、本实施例涉及到的菌株有：单核细胞增生李斯特氏菌(Listeriamonocytogenes)、屎肠球菌(Enterococcus faecium)、福氏志贺氏菌(Shigellaflexneri)、鲍曼不动杆菌(Acinetobacter baumannii)、大肠埃希菌(Escherichia coli)、铜绿假单胞菌(Pseudomonas aeruginosa)、新型隐球菌(Cryptococcus neoformans)购自中国科学院微生物研究所菌种保藏中心；痤疮丙酸杆菌(Propionibacterium acnes)购自广东省微生物菌种保藏中心；临床耐药菌QZ18080、QZ18081、QZ18050、QZ18055、QZ18109、QZ18110来源于福建医科大学附属第二医院检验科。
2、具体方法如下：
(1)活化菌种，将保种菌株划线于营养肉汤(NB：Nutrient broth)平板，37℃培养箱中静置培养(痤疮丙酸杆菌用脑心浸液(BHI：Brain heart immersion)+1％葡萄糖培养，并置于厌氧袋中培养；真菌划线于YPD平板，28℃培养箱中静置培养。)
(2)待菌落生长至合适大小，随机挑取3～5个单克隆于NB液体培养基中，37℃摇床，180rpm培养至对数期(痤疮丙酸杆菌挑克隆至BHI+1％葡萄糖培养，培养基液面上方加液体石蜡封顶；真菌挑克隆至YPD液体培养基，28℃摇床，230rpm培养至对数期)。
(3)4000g，离心3min收集细菌，最后用10mM磷酸钠缓冲液(NaPB，pH＝7.4)与MH液体培养基混合液稀释细菌(NaPB:MH＝3:2)，使得菌体的最终浓度约为5×105cfu/mL(真菌抗菌条件为NaPB:YPD＝3:2，菌体量约为5×104cfu/mL)。
(4)将已合成的Scybaumancin105-127粉末溶于无菌Milli-Q水，用0.22μm滤膜过滤，倍比稀释蛋白浓度至6μM、12μM、24μM、48μM、96μM、192μM；
(5)在96孔细胞培养板上，每种待测菌设置空白对照组、阴性对照组和待测实验组，每组设置三个平行：
a空白对照组：50μL待测蛋白样品和50μL稀释菌液的培养基
b阴性对照组：50μL无菌Milli-Q水和50μL菌悬液
c待测实验组：50μL待测蛋白样品和50μL菌悬液
将96孔细胞培养板置于37℃或28℃培养箱中，培养24h后吹打混匀取2μL点板至NB或YPD平板，于37℃或28℃培养，观察并记录MBC结果。
3、拟穴青蟹抗菌肽Scybaumancin105-127最小杀菌浓度(MBC)观察结果如表2所示。
表2拟穴青蟹抗菌肽Scybaumancin105-127的抗菌活性
注：MBC：最小杀菌浓度(μM)，用a～b表示。a：平板可见菌落生长的最高蛋白浓度；b：平板未见菌落生长的最低蛋白浓度
实施例3：Scybaumancin105-127杀菌动力学曲线
1、涉及到的菌株有：鲍曼不动杆菌CGMCC 1.6769和新型隐球菌CGMCC 2.1563。
2、具体方法如下：
抗菌实验方法同最小杀菌浓度的测定一致，抗菌肽和细菌共孵一定时间后，不同时间点取10μL共孵的混合液至490μL PBS，充分混匀后取50μL稀释液涂NB平板，如果预实验涂板的菌落计数<50个克隆，则取25μL共孵的混合液直接涂板，37℃培养箱静置培养12h后，进行菌落计数(真菌共孵的混合液用PBS稀释10倍后，涂YPD平板，置于28℃培养箱静置培养48h后，进行菌落计数)。
3、拟穴青蟹抗菌肽Scybaumancin105-127对鲍曼不动杆菌和新型隐球菌的杀菌动力学曲线如图1所示。
实施例4：扫描电镜观察Scybaumancin105-127处理后鲍曼不动杆菌的形态结构变化
1、涉及到的菌株有：
鲍曼不动杆菌的非耐药菌株CGMCC 1.6769和临床耐药菌株QZ18050。
2、具体实验方法如下：
(1)扫描电镜样品制备
活化菌种，待克隆长至合适大小，随机挑取3～5个克隆至NB液体培养基，摇至对数生长期，测OD600，离心去上清，用MH培养基重悬菌体，调至OD为0.1，取500μL菌液+等体积抗菌肽，37℃共孵30min后，离心去上清，用PBS洗一次后收集菌体。
(2)固定、清洗、滴片：
用300μL 2.5％戊二醛重悬收集的菌体，4℃冰箱固定1.5h或更长时间。
固定后的菌体用PBS洗三次(20min/次)后，制成高浓度悬液，滴至已切割好的载玻片上，黏附30min，用滤纸吸干后进行乙醇梯度脱水。
(3)脱水：
30％乙醇5min；50％乙醇5min；70％乙醇10min，可4℃冰箱过夜。
以上操作在冰盒里进行。
80％乙醇10min；95％乙醇15min；100％乙醇15min×2次。
(4)临界点干燥后，10mA电流，喷金60s；扫描电镜观察并拍片记录。
3、拟穴青蟹抗菌肽Scybaumancin105-127对鲍曼不动杆菌的非耐药菌CGMCC 1.6769和临床耐药菌株QZ18050形态结构变化如图2所示。
实施例5：MTS法检测和评价Scybaumancin105-127的细胞毒性
1、选取人肾上皮细胞(HEK-293T)、拟穴青蟹血细胞(Hemocytes)、鲤鱼上皮细胞(EPC)细胞，横坐标为Scybaumancin105-127蛋白浓度(μM)，纵坐标为细胞存活率(％)，对拟穴青蟹抗菌肽Scybaumancin105-127细胞毒性进行测定。
2、具体方法如下：
(1)收集生长状态良好的细胞，用对应的细胞培养基(HEK-293T、EPC用DMEM+10％FBS；Hemocytes用L15+5％FBS+1.2％NaCl)稀释细胞浓度至103～104个/mL，在96孔细胞培养板中每孔加入上述细胞悬液100μL，HEK-293T置于37℃细胞培养箱，5％CO2；EPC和Hemocytes置于28℃细胞培养箱，5％CO2条件下静置培养。
(2)小心吸出50μL培养基，加入含有不同浓度Scybaumancin105-127的相应培养基，置于相应的细胞条件下静置培养24h。
(3)加入20μL MTS-PMS混合溶液，孵育4h后，使用酶标仪测得OD492值，评价Scybaumancin105-127的细胞毒性。
3、结果如图3。在浓度0～96μM范围内，Scybaumancin105-127对HEK-293T、拟穴青蟹血细胞、EPC细胞无细胞毒性。
以上所述，仅为本发明较佳实施例而已，故不能依此限定本发明实施的范围，即依本发明专利范围及说明书内容所作的等效变化与修饰，皆应仍属本发明涵盖的范围内。
序列表
<110> 厦门大学
<120> 抗菌肽Scybaumancin105-127及其应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> PRT
<213> 拟穴青蟹(Scylla paramamosain)
<220>
<221> AMIDATION
<222> (23)..(23)
<400> 1
Val Val Thr Cys Arg Leu Ala His Met Ala Leu Lys Ser Ala Lys Ser
1 5 10 15
Ser Arg Ser Leu Leu Cys His
20
Claims (10)
1.一种抗菌肽Scybaumancin105-127，其氨基酸序列如SEQ ID NO.1所示。
2.一种权利要求1所述的抗菌肽Scybaumancin105-127在制备抗菌剂中的应用。
3.一种抗菌剂，其特征在于：所述抗菌剂包括氨基酸序列如SEQ ID NO.1所示的抗菌肽Scybaumancin105-127。
4.根据权利要求3所述的抗菌剂，其特征在于：所述抗菌剂用于抑制和/或杀灭革兰氏阳性菌、革兰氏阴性菌或真菌中的至少一种。
5.根据权利要求4所述的抗菌剂，其特征在于：所述革兰氏阳性菌包括单核细胞增生李斯特氏菌、屎肠球菌、耐药屎肠球菌或痤疮丙酸杆菌中的至少一种。
6.根据权利要求4所述的抗菌剂，其特征在于：所述革兰氏阴性菌包括福氏志贺氏菌、鲍曼不动杆菌、耐药鲍曼不动杆菌、大肠埃希菌、耐药大肠埃希菌或铜绿假单胞菌中的至少一种。
7.根据权利要求4所述的抗菌剂，其特征在于：所述真菌包括新型隐球菌。
8.一种权利要求1所述的抗菌肽Scybaumancin105-127在制备食品添加剂中的应用。
9.一种食品添加剂，其特征在于：所述食品添加剂包括氨基酸序列如SEQ ID NO.1所示的抗菌肽Scybaumancin105-127。
10.根据权利要求9所述的食品添加剂，其特征在于：所述食品添加剂用于抑制和/或杀灭食源性污染的单核细胞增生李斯特氏菌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110261150.8A CN113121666B (zh) | 2021-03-10 | 2021-03-10 | 抗菌肽Scybaumancin105-127及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110261150.8A CN113121666B (zh) | 2021-03-10 | 2021-03-10 | 抗菌肽Scybaumancin105-127及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113121666A true CN113121666A (zh) | 2021-07-16 |
| CN113121666B CN113121666B (zh) | 2023-09-12 |
Family
ID=76773008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110261150.8A Active CN113121666B (zh) | 2021-03-10 | 2021-03-10 | 抗菌肽Scybaumancin105-127及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113121666B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113999296A (zh) * | 2021-11-04 | 2022-02-01 | 厦门大学 | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 |
| CN114106103A (zh) * | 2022-01-24 | 2022-03-01 | 中国科学院南海海洋研究所 | 一种贝类来源的抗菌肽p-amp108及在制备治疗痤疮药物中的应用 |
| CN116143883A (zh) * | 2022-10-19 | 2023-05-23 | 厦门大学 | 一种广谱抗微生物肽Scymicrosin7-26及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003263328A1 (en) * | 2002-09-09 | 2004-03-29 | Trigen Limited | Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| DE102005029704A1 (de) * | 2005-06-24 | 2007-01-11 | Basf Ag | Verwendung von Hydrophobin-Polypeptiden sowie Konjugaten aus Hydrophobin-Polypeptiden mit Wirk-oder Effektstoffen und ihre Herstellung sowie deren Einsatz in der Kosmetik |
| CN108929547A (zh) * | 2018-06-26 | 2018-12-04 | 铜陵市明科包装技术有限公司 | 草鱼鱼鳞提取物制备抗菌膜的工艺 |
| CN110776560A (zh) * | 2019-10-09 | 2020-02-11 | 厦门大学 | 一种黑鲷抗菌肽AS-hepc3(48-56)及其应用 |
| CN111087460A (zh) * | 2020-01-14 | 2020-05-01 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种广谱型抗菌肽及其应用 |
| CN112159460A (zh) * | 2020-09-29 | 2021-01-01 | 厦门大学 | 一种拟穴青蟹抗菌肽Spamprin4-23及其应用 |
-
2021
- 2021-03-10 CN CN202110261150.8A patent/CN113121666B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003263328A1 (en) * | 2002-09-09 | 2004-03-29 | Trigen Limited | Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| DE102005029704A1 (de) * | 2005-06-24 | 2007-01-11 | Basf Ag | Verwendung von Hydrophobin-Polypeptiden sowie Konjugaten aus Hydrophobin-Polypeptiden mit Wirk-oder Effektstoffen und ihre Herstellung sowie deren Einsatz in der Kosmetik |
| CN108929547A (zh) * | 2018-06-26 | 2018-12-04 | 铜陵市明科包装技术有限公司 | 草鱼鱼鳞提取物制备抗菌膜的工艺 |
| CN110776560A (zh) * | 2019-10-09 | 2020-02-11 | 厦门大学 | 一种黑鲷抗菌肽AS-hepc3(48-56)及其应用 |
| CN111087460A (zh) * | 2020-01-14 | 2020-05-01 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种广谱型抗菌肽及其应用 |
| CN112159460A (zh) * | 2020-09-29 | 2021-01-01 | 厦门大学 | 一种拟穴青蟹抗菌肽Spamprin4-23及其应用 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113999296A (zh) * | 2021-11-04 | 2022-02-01 | 厦门大学 | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 |
| CN113999296B (zh) * | 2021-11-04 | 2022-11-01 | 厦门大学 | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 |
| CN114106103A (zh) * | 2022-01-24 | 2022-03-01 | 中国科学院南海海洋研究所 | 一种贝类来源的抗菌肽p-amp108及在制备治疗痤疮药物中的应用 |
| CN116143883A (zh) * | 2022-10-19 | 2023-05-23 | 厦门大学 | 一种广谱抗微生物肽Scymicrosin7-26及其应用 |
| CN116143883B (zh) * | 2022-10-19 | 2024-09-06 | 厦门大学 | 一种广谱抗微生物肽Scymicrosin7-26及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113121666B (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113121666B (zh) | 抗菌肽Scybaumancin105-127及其应用 | |
| CN112940082B (zh) | 一种抗菌肽及其应用 | |
| CN112724221B (zh) | 拟穴青蟹抗菌肽Spamplin58-82及其应用 | |
| CN112159460B (zh) | 一种拟穴青蟹抗菌肽Spamprin4-23及其应用 | |
| US20230404076A1 (en) | Antimicrobial peptide spampcin56-86 from scylla paramamosain and applications thereof | |
| CN114014923B (zh) | 拟穴青蟹抗菌多肽Sp-LECin及其应用 | |
| CN110028568B (zh) | 一种拟穴青蟹抗菌多肽Sp-NPFin及其应用 | |
| CN114716512B (zh) | 一种青蟹广谱抗菌肽Scyampcin44-63及其应用 | |
| CN110776560B (zh) | 一种黑鲷抗菌肽AS-hepc3(48-56)及其应用 | |
| CN113999296B (zh) | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 | |
| CN106146643B (zh) | 人α‑防御素5改造体及其应用 | |
| CN101333247B (zh) | 从东北林蛙皮肤中分离出的抗菌肽及其在抗菌药物中的应用 | |
| CN114516899A (zh) | 抗菌肽yhx-5及其应用 | |
| Van Rensburg | The tyrocidines in the creation of antimicrobial cellulose and sterilizing materials | |
| CN110074179B (zh) | 抗菌肽Jelleine-I在制备防治柑橘果实采后绿霉病的药物中的应用 | |
| CN114773436B (zh) | 一种拟穴青蟹抗菌多肽SpRR20及其应用 | |
| CN114957429B (zh) | 一种青蟹广谱抗菌多肽Scyrephemin60-81及其应用 | |
| CN116143883B (zh) | 一种广谱抗微生物肽Scymicrosin7-26及其应用 | |
| CN114957430B (zh) | 一种拟穴青蟹抗菌多肽Sparepcin173-194及其应用 | |
| CN116925204A (zh) | 一种拟穴青蟹抗菌多肽Spgilstin10-33及其应用 | |
| CN103193877B (zh) | 一种蛋白质及其在制备抗微生物产品中的应用 | |
| CN115246876B (zh) | 一种拟穴青蟹抗菌多肽Scyrepsin34-55及其应用 | |
| CN116768981A (zh) | 一种青蟹抗菌肽Scyllacin63-82及其应用 | |
| CN117264040A (zh) | 一种拟穴青蟹新型抗菌肽Scyreptin及其应用 | |
| CN117567584A (zh) | 一种大黄鱼抗菌多肽Larimicin及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |